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ABSTRACT  
Amyotrophic lateral sclerosis (ALS) is an adult onset disorder characterised by progressive 
neuromuscular junction (NMJ) dismantling and degeneration of motor neurons leading to 
atrophy and paralysis of voluntary muscles responsible for motion and breathing. Except for 
a minority of patients harbouring genetic mutations, the origin of most ALS cases remains 
elusive. Peripheral tissues, and particularly skeletal muscle, have lately demonstrated an 
active contribution to disease pathology attracting a growing interest for these tissues as 
therapeutic targets in ALS. In this sense molecular mechanisms essential for cell and tissue 
homeostasis have been shown to be de-regulated in the disease. These include muscle 
metabolism and mitochondrial activity, RNA processing, tissue-resident stem cell function 
responsible for muscle regeneration, and proteostasis that regulates muscle mass in 
adulthood. 
This review aims to compile scientific evidence that demonstrates the role of skeletal 
muscle in ALS pathology and serve as reference for development of novel therapeutic 
strategies targeting this tissue to delay disease onset and progression. 
NON-STANDARD ABBREVIATIONS 
Neuromuscular junction (NMJ), mutant SOD1 (mSOD1), mitochondrial DNA (mtDNA), 
dipeptide repeat (DPR), RNA binding proteins (RBPs), extensor digitorum longus (EDL), slow-




Neurodegeneration/neuroprotection, intercellular signalling, cellular repair mechanisms, 
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INTRODUCTION 
Amyotrophic Lateral Sclerosis (ALS) is a neuromuscular disorder of unknown etiology. While 
the vast majority of the ALS cases are sporadic, a minority (5-10%) are caused by inherited 
familiar gene alterations (Byrne et al., 2011). Mutations in more than 25 ALS-linked genes 
have been described, with those encoding cytoplasmic superoxide dismutase 1 (Sod1) and 
guanine nucleotide exchange factor C9orf72 being most frequently affected (Al-Chalabi & 
Hardiman, 2013; Nguyen, Van Broeckhoven, & van der Zee, 2018). Disease onset is 
secondary to upper and lower motor neuron degeneration, appears around 55-60 years, 
and is accompanied with cramping and twitching, hyperreflexia, spasticity, severe muscle 
weakness and atrophy in limbs and trunk (spinal form) or dysarthria and dysphagia (bulbar 
form). As disease progresses, patients are also at risk of choking on food and aspiration 
pneumonia. ALS is a fast-decline disorder that progresses to paralysis of voluntary muscles 
including diaphragm and intercostals responsible for breathing, with an average life 
expectancy of 3-5 years after diagnosis. 
Unlike other neuromuscular disorders such as spinal and bulbar muscular atrophy (SBMA), 
where toxicity associated to androgen receptor mutation in skeletal muscle is widely 
accepted to contribute to disease pathogenesis and progression and this tissue is a target 
for drug development (Manzano et al., 2018), controversy exists on the actual etiology of 
denervation, muscle atrophy and weakness in ALS. Whether it is solely a consequence of 
motor neuron degeneration or there is also a contribution from pathogenic mechanisms 
arising from skeletal muscle or other peripheral tissues is still under debate. Similarities in 
skeletal muscle between ALS and SBMA include incomplete myoblast differentiation in vitro 
(Malena et al., 2013), histological signs of neurogenic together with primary myogenic 
defects (i.e. presence of angulated and grouped fibers and centrally nucleated and necrotic 
myofibers) and glycolytic-to-oxidative metabolic fiber-type switching (Rocchi et al., 2016). 
However, mutant SOD1 (mSOD1) gene excision or inhibition of its transcription or protein 
expression in skeletal muscle does not preserve grip strength, nor affects survival or disease 
onset in the SOD1-G93A mouse model of ALS (Miller et al., 2006). On the contrary, latter 
studies have shown that restricted expression of mSOD1 in skeletal muscle of mice at similar 
levels as in the SOD1-G93A mouse model (where a human SOD1 enzyme carrying a G93 to A 
mutation is ubiquitously expressed), causes muscle atrophy and reduces tetanic and specific 
force, displaying neuromuscular junction abnormalities and a motor neuron distal 
axonopathy (G. Dobrowolny et al., 2008) (Wong & Martin, 2010). These results highlight the 
importance of unravelling the temporal dynamics and mechanisms involved in skeletal 
muscle phenotype in ALS.  
This review discusses the current understanding about the role of skeletal muscle in ALS, 
focussing on the pathogenic molecular pathways and the potential therapeutic approaches 
targeting this tissue (Figure 1). This information is aimed to be useful in the search for novel 
mechanisms, a better management of ALS patients and the design of novel drugs and less 
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NEUROMUSCULAR JUNCTION AND THE DYING BACK PHENOMENON 
Motor neuron nerve terminals and muscle fibers in vertebrates communicate through highly 
specialized cholinergic synapses, the neuromuscular junctions (NMJ). These presynaptic 
terminals receive action potentials and trigger the release of neurotransmitter acetylcholine 
that subsequently activates nicotinic acetylcholine receptors in postsynaptic muscle fibers 
enabling muscle contraction. The NMJ also contains other essential synapse-associated cells, 
including perisynaptic Schwann cells involved in the development, maintenance and 
regeneration of NMJ function through trophic cues (reviewed in (Lepore, Casola, 
Dobrowolny, & Musaro, 2019). Increasing evidence from ALS animal models such as those of 
various mSOD1, mutant fused in sarcoma (FUS) and nuclear localization -defective TAR DNA-
binding protein 43 (TDP-43) indicates that NMJ defects take place in the early stage of the 
disease in ALS, the fast-type (fast-fatigable) neuromuscular synapses being the most 
vulnerable (Acevedo-Arozena et al., 2011; Fischer et al., 2004; Frey et al., 2000; Hadzipasic 
et al., 2014; Hegedus, Putman, & Gordon, 2007; Pun, Santos, Saxena, Xu, & Caroni, 2006; 
Sharma et al., 2016; Spiller et al., 2016). From the NMJ, the pathology proceeds along the 
axons to the motor neuron cell body with a “dying-back” pattern, leading to motor neuron 
death as a relatively late event. These observations are consistent with reports that 
expression of mSOD1 in motor neurons alone is not sufficient to cause ALS-like symptoms in 
mice (Lino, Schneider, & Caroni, 2002; Pramatarova, Laganiere, Roussel, Brisebois, & 
Rouleau, 2001; Yamanaka et al., 2008), although some studies disagree with this (Jaarsma, 
Teuling, Haasdijk, De Zeeuw, & Hoogenraad, 2008; L. Wang et al., 2008). However, 
preventing motor neuron apoptosis does not ultimately protect from NMJ denervation 
(Gould et al., 2006). To what extent and in which specific conditions the NMJ stability is 
determined by signals originating from one or another tissue or cell type remains under 
investigation. The contribution to motor neuron degeneration by non-neural cells including 
glial cells (Boillee, Yamanaka, et al., 2006; Carrasco, Bichler, Seburn, & Pinter, 2010; Clement 
et al., 2003; Ferraiuolo et al., 2016; Yamanaka et al., 2008) and skeletal muscle (Lepore et 
al., 2019; Wong & Martin, 2010) is accumulating, and suggests that alterations in multiple 
cell types act synergistically to exacerbate the disease (Boillee, Vande Velde, & Cleveland, 
2006).  
Although direct investigation on sequential molecular events leading to death of motor 
neurons is somewhat limited in ALS patients, it is known that synaptic protein composition 
is disturbed in NMJ associated with severely affected muscles of ALS patients, whereas 
those preserved (such as extraocular muscles) are only mildly affected (Liu, Brannstrom, 
Andersen, & Pedrosa-Domellof, 2013). This suggests that molecules involved in NMJ 
function and stability could serve as early biomarkers for the distal axonopathies, and that 
interventions that aim to preserve NMJ could serve for therapeutic purposes. One of such 
factors is RTN4 (Nogo-A), a neurite outgrowth inhibitor overexpressed in the skeletal muscle 
of ALS patients (P. F. Pradat et al., 2007), where its levels also correlate with disease severity 
(Jokic et al., 2005) and endplate denervation (Bruneteau et al., 2015). In mSOD1 mice RTN4 
promotes denervation (Jokic et al., 2006) and antibody treatment against this protein 
ameliorates the disease progression and, therefore, may serve as a promising therapeutic 
target (Bros-Facer et al., 2014). However, it is not yet mechanistically clear how RTN4 
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promotes denervation in ALS as its expression has been described to be limited in slow 
muscle fibers (Jokic 2005) which in ALS are generally regarded as the most resistant ones. 
Additionally, some studies have described increased immunoreactivity of RTN4 in other 
muscle pathologies (Wojcik, Engel, & Askanas, 2006) which may limit its use as a highly 
specific ALS biomarker.  
 
IMPAIRMENT OF MUSCLE MITOCHONDRIAL ACTIVITY AND METABOLISM 
Although much less studied than for motor neurons, mitochondrial abnormalities have been 
also described in skeletal muscle from ALS patients. Those include ultrastructural changes 
such as swelling, paracrystalline inclusions, disruption of the cristae and dilution of the 
matrix (Napoli et al., 2011). These aberrant mitochondria have been located frequently in 
aggregates adjacent to subsarcolemma (Chung & Suh, 2002). Manganese superoxide 
dismutase (Mn-SOD) is located in mitochondria being responsible for detoxification of the 
superoxide anion radical (O2–•), the major ROS generated in this organelle into molecular 
oxygen (O2) and hydrogen peroxide (H2O2) (Skulachev, 1996), representing a cellular 
defence against reactive oxidative species (ROS).  A 40% reduction in Mn-SOD has been 
found in membrane fractions obtained skeletal muscle homogenates from sporadic ALS 
patient (Vielhaber et al., 2000). In agreement, accumulation of ROS and oxidative stress 
have been reported in skeletal muscle from ALS patients and SOD1-G93A mice (Yajuan Xiao 
et al., 2018). These mice also showed an increase in Cyclophilin D (CypD) expression which 
promotes the opening of the mitochondrial permeability transition pore (mPTP), increasing 
mitochondria membrane depolarization and the further generation of ROS species (Yajuan 
Xiao et al., 2018; Zorov, Juhaszova, & Sollott, 2014). 
In turn, excessive ROS production is reported to exacerbate mitochondrial impairment by 
damaging mitochondrial DNA (mtDNA). Multiple mtDNA deletions, depletion of intact 
mtDNA and decreased activity of the mitochondrial encoded enzymes responsible for 
respiratory chain (NADH:cytochrome c and  NADH:Coenzyme Q  oxidoreductases and 
Cyclooxygenase (COX)) have been described in skeletal muscle from familial ALS patients 
(Artuso et al., 2013; Crugnola et al., 2010; Vielhaber et al., 2000; Wiedemann et al., 1998), 
demonstrating a deficient mitochondrial respiration chain and ATP generation. In line with 
the raising ROS concentration and oxidative stress and perhaps as a compensatory 
mechanism to recover redox state in the myofiber, superoxide dismutase and catalase 
activities are boosted in mSOD1 skeletal muscle (Leclerc et al., 2001; Mahoney, Kaczor, 
Bourgeois, Yasuda, & Tarnopolsky, 2006). Accumulation of misfolded mutant proteins 
observed in skeletal muscle may also aggravate this phenotype since protein folding control 
in the ER lumen is a highly energy-demanding process, forcing mitochondrial oxidative 
phosphorylation and ROS generation (Bhattacharya, Wei, Hamilton, & Chaudhuri, 2014; 
Loeffler, Picchiarelli, Dupuis, & Gonzalez De Aguilar, 2016; Wei, Bhattacharya, Hamilton, 
Jernigan, & Chaudhuri, 2013).  
Besides SOD1, animal models carrying mutations in other ALS-related genes present in 
sporadic ALS cases, such as vesicle-associated membrane protein-associated protein 
VAPB/ALS8 also show energy deficits. VAPB mutants have reduced ATP levels and promote 
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myofiber fat infiltration through FoxO pathway, suggesting the activation of metabolic 
changes to compensate for mitochondria dysfunction (Han et al., 2013).  
In line with the pivotal role of defective mitochondrial respiratory chain and oxidative stress 
in ALS skeletal muscle, increasing levels of PGC-1 alpha, a transcription coactivator that 
promotes mitochondrial biogenesis, can improve muscle function even at late stages of the 
disease (Thau et al., 2012). In this same line, genetic ablation of Parkin, a mitochondrial 
ubiquitin ligase and negative regulator of PGC-1 alpha, attenuates motor neuron loss and 
denervation in the SOD1-G93A mouse model of ALS, partially rescuing mitochondrial 
dysfunction and PGC1 alpha expression, at least in spinal cord (Palomo et al., 2018).  
Other than underfeeding, oxidative stress and mitochondrial dysfunction, the origin of the 
hypermetabolic state and elevated resting energy expenditure observed in ALS still remains 
obscure, especially considering the loss of mass and function of skeletal muscle, the highest 
energy-consuming tissue of the body, along disease course (Bouteloup et al., 2009; Ferri & 
Coccurello, 2017; Kasarskis et al., 2014).  
Nevertheless, mapping of denervation patterns in SOD1-G93A mice shows that fast-
fatigable motor units innervating myofibers with type II glycolytic metabolism are 
particularly susceptible for degeneration even before motor symptoms (Frey et al., 2000; 
Hegedus, Putman, Tyreman, & Gordon, 2008). Skeletal muscle is a major glucose storage in 
the form of glycogen, that is transformed into ATP through glycolysis. The dysfunction of 
fast-twitch type IIb myofibers in ALS is consistent with glucose intolerance and insulin 
resistance reported in ALS patients (P. F. Pradat et al., 2010; Reyes, Perurena, Festoff, 
Jorgensen, & Moore, 1984) and preferential metabolic shifting toward free-fatty acid beta-
oxidation rather than glycolysis, observed in mSOD1 mice models before disease onset 
(Scaricamazza et al., 2020). Increased levels of pyruvate dehydrogenase kinase 4 (PDK4) and 
inhibition of pyruvate dehydrogenase complex (PDH) and phosphofructokinase 1 (PFK1) 
leads to glycogen accumulation and metabolic switch towards lipid catabolism and 
consequently, an increase of reactive oxygen species that aggravate the mitochondrial 
dysfunction (Gabriella Dobrowolny et al., 2018; Palamiuc et al., 2015). Reverting this change 
by daily administration of dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase 
kinase 4 activity, to SOD1-G86R mice facilitates the entry of pyruvate into the Krebs cycle 
and glycolysis, restoring PGC-1 alpha and its target gene Mfn2, protecting muscle 
mitochondria and preventing denervation and muscle atrophy (Gabriella Dobrowolny et al., 
2018; Palamiuc et al., 2015). 
In line with the preferential fatty acid oxidation in skeletal muscle from ALS patients, 
gastrointestinal absorption of lipids and peripheral clearance of triglyceride-rich lipoproteins 
were markedly increased in these subjects. Accordingly, high fat diets exert extended 
survival by 20% in mutant SOD1 mice and ameliorated energy over-expenditure and disease 
outcomes in ALS patients (Dupuis, Oudart, René, Gonzalez de Aguilar, & Loeffler, 2004; 
Fergani et al., 2007; Mattson, Cutler, & Camandola, 2007; Oliván et al., 2014).  
On the contrary, ablation of the AMP-activated protein kinase (AMPK) in skeletal muscle 
from wildtype mice promotes gait disturbances that resemble those observed in mSOD1 
mice (Vergouts et al., 2015). AMPK acts as an energy sensor, activating both fatty acid 
oxidation and mitochondria biogenesis but also glycolysis upon muscle ATP depletion 
(Kjøbsted et al., 2018). Therefore, detrimental effects of AMPK reduction in ALS are likely to 
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reflect accelerated hypermetabolism and energy deficit through inhibition of both catabolic 
pathways. 
Phosphorylated TDP-43 aggregates are also present in skeletal muscle biopsies from ALS 
patients (Mori et al., 2019), and this protein is proposed to participate somehow in energy 
balance homeostasis in this tissue. In this line, myofibers from transgenic mice over 
expressing wild-type TDP-43 show impaired insulin mediated glucose uptake (Stallings et al., 
2013) and postnatal conditional TDP-43 knockout mice exhibit weight loss and fat depletion, 
confirming that metabolic changes in ALS skeletal muscle are not only associated to mSOD1 
pathology. 
Metabolism of alternative sources of ATP such as creatine phosphate is also impaired with 
67% decrease in mitochondrial creatine kinase activity, at least in spinal cord from mSOD1 
mice (Wendt et al., 2002). This deficit cannot be restored by creatine monohydrate intake, 
although muscle atrophy is partly mitigated (Derave et al., 2003). Unfortunately, creatine 
monohydrate did not extend survival nor improved fatigue during isometric contraction in 
ALS patients (Table1) (Rosenfeld et al., 2008). 
Taking together these data indicate the existence of an adaptative switch towards oxidative 
metabolism together with disruption of the main mechanisms for cellular ATP production in 
ALS skeletal muscle. However, from the therapeutic perspective, mitochondrial co-factors 
and modulators of oxidative phosphorylation have failed to provide clinical evidences (Table 
1), which highlights the need for a better understanding of the underlying origin of 
mitochondrial impairment, oxidative stress and energy imbalance in ALS. This is especially 
relevant in skeletal muscle, since this tissue may account up to 60% oxygen and nutrient 
body consumption, and muscle atrophy represents one of the earliest events in the disease. 
PROTEOSTASIS IN ALS MUSCLE 
In adults, skeletal muscle mass is dynamically regulated through balance between protein 
synthesis and degradation mechanisms in combination with signalling networks for protein 
quality control (PQC), trafficking and clearance. These are all tightly interconnected 
mechanisms to regulate protein homeostasis, or proteostasis (for review see (Anthony, 
2016).  
Muscle protein synthesis is regulated at translational level and relies on the formation of 
two intracellular structures, the ternary initiation complex (composed of methionyl tRNA, 
eukaryotic initiation factor (eIF) 2 and GTP) and the eIF4 ribosomal complex. 
Phosphorylation of eIF2 and eIF4 controls the assembly of these complexes and, therefore, 
the protein synthesis in adult skeletal muscle (Jefferson & Kimball, 2001). On the other 
hand, proteolytic systems relevant for skeletal muscle mass are mainly the autophagy 
lysosomal, the ubiquitin proteasome pathway and the unfolded protein response (UPR). 
Besides skeletal muscle mass, these degradative mechanisms, together with the molecular 
chaperones such as heat shock proteins (HSPs), also conform the PQC system to target 
misfolded proteins for degradation or refolding and prevent aggregation and toxicity 
(Anthony, 2016; Tipton, Hamilton, & Gallagher, 2018). Failure in any of these mechanisms 
has been linked to denervation, atrophy and muscle wasting (Sandri, 2013). 
Skeletal muscle is typically more efficient in activating the proteolytic and PCQ mechanisms 
compared to nervous system (Onesto et al., 2011). Impairment in several proteostatic 
mechanisms has been reported in skeletal muscle of patients with neuromuscular 
conditions such as ALS. Regarding protein anabolic mechanisms, a translational repression 
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and, therefore, a reduced protein synthesis is associated to many mutant ALS-proteins 
including SOD1, TDP-43, FUS, and C9ORF72 (Kamelgarn et al., 2018; Kanekura et al., 2016). 
The exact causes of this blockade remain to be elucidated although stress granule formation 
and sequestering of mRNAs and translation initiation factors, including eIF2, within mutant 
protein aggregates have been demonstrated (Cestra, Rossi, Di Salvio, & Cozzolino, 2017).   
To the best of these authors’ knowledge no studies have been carried out in the search for 
stress granules in skeletal muscle from ALS patients or experimental models. However, 
dipeptide repeat (DPRs) inclusions, have been described in skeletal muscle from mutant 
C9orf72 ALS patients and myocytes differentiated from induced pluripotent stem cells, and 
are particularly associated to atrophic myofibers (M. D. Cykowski et al., 2019; Lynch et al., 
2019). These dipeptide repeats are formed by repeat-associated non-ATG (RAN) translation 
and in studies carried out in brain sections from ALS patients, one of these repeats (proline-
arginine) has been shown to complex with more than a hundred ribosomal proteins and 
translation initiation factors restraining the access to mRNA and impeding protein 
translation (Kanekura et al., 2016). 
The main catabolic mechanism that targets misfolded proteins is autophagy, which also 
conducts bulk degradation and recycling of cellular material and organelles. Under normal 
diet, autophagic markers such as Beclin1 (BECN1/ATG6), microtubule-associated protein LC3 
(MAP1LC3A) and sequestosome 1 (SQSTM1/p62) and autophagosome formation have been 
found upregulated in muscle from mSOD1 mice (Crippa et al., 2013; G. Dobrowolny et al., 
2008; Oliván et al., 2015; Y. Xiao et al., 2015). Starvation stress boosts autophagic flux, 
increasing autophagosome and lysosome formation and, thus, vesicle cargo degradation in 
skeletal muscle of wild type mice but not in that of mSOD1 mice (Y. Xiao et al., 2015). This 
could be explained by a caspase 3 -dependent cleavage of BECN1 autophagy promoter 
observed in this ALS model (Y. Xiao et al., 2015). Similarly, increased p62 and LC3 protein 
levels and autophagosomes in cell cultures under nutrient rich medium but failed activation 
of autophagosome formation after stress-induced starvation in fibroblasts from ALS patients 
carrying the C9orf72 repeat-expansion (Aoki et al., 2017). 
Mutations in a gene encoding the valosin-containing protein (VCP) can also cause familial 
ALS. VCP is a member of the ATPase family critical for protein homeostasis in muscles and 
neurons (Johnson, Shu, Hauswirth, Tong, & Davis, 2015). Chemical or genetic inhibition of 
VCP interfere with the maturation of autophagosomes leading to accumulation and 
hampering the fusion with lysosomes. In VCP-mutant mouse skeletal muscle there is a 
diminished activity of mTOR, an inhibitor of autophagosome formation, and this is 
concomitant with upregulation of autophagosome biogenesis. A further inhibition of 
mTORC1 activity with rapamycin exacerbated weakness, muscle atrophy and vacuolation 
and increased p62 and LC3-positive vesicle accumulation in skeletal muscle from VCP-
mutant mice (Ching et al., 2013), suggesting that mutations in VCP impair autophagosome 
degradation but no biogenesis. In line with these findings, the loss of a novel VCP interactor 
Washc4/Swip (WASH complex subunit 4) in the vertebrate model zebrafish alters 
autophagy-mediated proteostasis in striated muscle cells (Kustermann et al., 2018).  
Taken together these data show compelling evidence that gene mutations found in ALS 
patients impair different stages of the autophagy flux, and this phenotype is exacerbated 
upon stress induced by starvation or rapamycin treatment. In scenario, therapeutic 
interventions in ALS models to simply stimulate autophagic flux might be detrimental, 
enhancing undigested autophagosome cytoplasmic accumulation.  
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Indeed, in the mutant FUS fly model of familiar ALS, overexpression of an ankyrin-repeat 
and KH-domain containing protein Mask, enhanced autophagosome degradation through 
lysosomal acidification, ameliorating protein aggregation in muscle from these flies (Zhu, 
Zhang, Tian, & Wu, 2017). Human ortholog of Mask ANKHD1, is highly expressed in skeletal 
muscle and its function in involved in endosomal maturation (Kitamata, Hanawa-Suetsugu, 
Maruyama, & Suetsugu, 2019). 
 
The unfolded protein response (UPR) is a protein quality control mechanism that promotes 
refolding or degradation of misfolded proteins to restore the physiological equilibrium 
within the cell. Accumulation of aberrant proteins in endoplasmic reticulum (ER) lumen 
leads to stress and triggers the UPR by inducing expression of heat shock protein 
chaperones (HSPs) to refold the proteins or proteasome degradative pathway via 
polyubiquitin chain tagging of the target protein. Failure or overwhelming of these pathways 
leads to UPR-induced cell apoptosis (Kaganovich, Kopito, & Frydman, 2008).  
ER stress and UPR modulation by mutant ALS proteins have been reported in skeletal 
muscle from SOD1 ALS models (Chen, Wang, & Chin, 2015; Loeffler et al., 2016). In this 
sense, we observed a significant upregulation of proteasome activity was at pre-
symptomatic stage, while symptomatic and terminal stages showed a reduction in this 
pathway in skeletal muscle from mSOD1 mice (Oliván et al., 2015). Likewise, ubiquitin-
positive inclusions have been also detected in muscles from C9ORF72 ALS patients, 
suggesting an implication of the ubiquitin proteasome pathway in the pathogenesis of the 
C9-related ALS (Maurel et al., 2018). Small heat shock proteins such as B8 (HSPB8), are also 
highly expressed in skeletal muscle from ALS models and might contribute to autophagy 
activation and protein aggregate clearance (Rusmini et al., 2017) in agreement with a 
mutual interplay between autophagy and the UPR. This hypothesis is supported by 
overexpression of viral and Drosophila homologs of HSPB8, ICP10PK and HSP67Bc 
respectively, to preserve neuromuscular junction and ameliorate disease outcomes in the 
SOD1-G93A mice (Aurelian, Laing, & Lee, 2012; Ritson et al., 2010). 
Further evidences of UPR induction and autophagy regulation upon mutant ALS-protein 
expression have emerged from in vitro experiments where the C2C12 mouse myoblasts and 
mouse embryonic fibroblasts were transfected with mutant versions of VAPB and ER-Sigma 
receptor-1 (SIGMAR1) respectively, showing UPR activation, protein aggregation and 
autophagy impairment (Dreser et al., 2017; Y. Tokutake et al., 2015).  
Epigenetic regulators have also been quantified within skeletal muscle from ALS patients. 
Transcript levels of histone deacetylase 4 (HDAC4) are upregulated in patients with fast 
disease progression and HDCA4 protein levels negatively correlating with the extent of 
reinnervation observed on muscle biopsies from patients (Bruneteau et al., 2013). By 
altering acetylation of histones, HDACs can modulate gene expression of UPR proteins, 
regulating the levels of heat shock chaperones, decreasing ubiquitination and proteasomal 
degradation. Interestingly, skeletal muscle restricted knockout of HDAC4 in mSOD1 mice 
results in levels of poly-ubiquitinated proteins and proteasome activity similar to those of 
wildtype control animals (Pigna et al., 2019). A summary of abnormalities in proteostasis 
mechanisms observed in ALS is depicted in Figure 2. 
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From the therapeutic perspective, promising strategies are based on increasing the content 
of neurotrophic factors in ALS muscle to counteract the impairment in proteostasis and to 
maintain muscle physiology. This is the case of insulin-like growth factor 1 (Igf1), which 
stimulates growth and development through satellite cell myogenesis but also increasing 
protein synthesis mediated by Akt-mTOR and inhibiting autophagy (see (Vainshtein & 
Sandri, 2020)for review). The upregulation of Igf1 in muscle, using recombinant plasmid 
injections or MLC/mIgf1 mouse (which selectively expresses mouse Igf1 under the 
transcriptional controls of myosin light chain, MLC,  promoter in fast-twitch fibers) cross 
breeding with mSOD1 mice can improve hindlimb muscle strength, as well as increase 
motor unit and motor neuron survival (Gabriella Dobrowolny et al., 2005; Riddoch-
Contreras et al., 2009). The use of subcutaneous implants of dihydrotestosterone in mutant 
SOD1-G93A mice at early symptomatic age also induces increasing levels of Igf1, attenuates 
neuromuscular junction denervation and improves motor behaviour, increasing the lifespan 
in these animals (Yoo & Ko, 2012). 
In a clinical trial carried out in North America, subcutaneous recombinant human IGF1 
delayed functional impairment and symptom progression as measured by AALS total score 
(Lai et al., 1997). However, a phase 3 and a 2-year placebo-controlled trial in European 
patients did not corroborate these results, failing to detect changes in muscle strength or 
function (Borasio et al., 1998; Sorenson et al., 2008). Unfortunately, lack of information on 
the IGF1 concentration in skeletal muscle during these clinical trials and differences in 
doses, timeframes and systemic rather than muscle-targeted delivery systems for IGF1 in 
pre-clinical versus clinical trials hamper comparison of results among these studies (Table 1).  
Conversely, other therapeutic approaches have been designed to assist refolding or 
clearance of ALS-linked proteins i.e. by autophagy or UPS initiation or enhancement of heat 
shock protein or chaperone translation in patients (Table 1). The use of recombinant 
plasmids to overexpress a selective chaperone (HSPB8) and co-chaperones (BAG1 and 
BAG3) can modulate autophagy and proteasome by removing TDP-25 (the C-terminal 25 
kDa fragment of TDP-43) inclusions in immortalized motor neuron -like (NSC34) cells and 
stabilized myoblasts (Cicardi et al., 2018).  
These data highlight the therapeutic potential of regulating proteostasis network in ALS 
skeletal muscle. However, they also remark the need to finely monitor drug concentration in 
skeletal muscle and proteins or nucleic acids targeted since these mechanisms are already 
stressed and challenged by misfolded proteins, abnormal organelles and aggregated nucleic 
acids and peptides. Excessive boosting of autophagy and UPR or without further facilitation 
in the clearance of the cargo might cause overload and be detrimental for the overall 
balance between protein synthesis and degradation and thus contribute to skeletal muscle 
atrophy and denervation in ALS.  
RNA METABOLISM IN ALS SKELETAL MUSCLE 
Products of approximately half of the known ALS genes are involved in regulation of RNA 
processing, including transcription, splicing, stabilization, RNA trafficking and processing of 
non-coding RNAs (Butti & Patten, 2019). Among these, C9orf72, SOD1, TDP-43 and FUS 
mutations count for 40-50% of the genetic ALS cases. Many of the ALS-linked proteins, such 
as TDP-43, FUS, HNRNPs A1 and A2B, TAF15, EWSR1, MATR3 and TIA1, are RNA binding 
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proteins (RBPs) containing one or more RNA recognition motifs involved in their normal 
biological function. These proteins generally also contain low complexity, or prion-like 
domain that allows phase separation to microdomains where RNA processing takes place.  
Indeed, many of ALS-linked proteins are found to accumulate in RNA foci such as 
cytoplasmic stress granules or nuclear paraspeckles, both structures being membrane-less 
organelles implicated in ALS (An, Tan, & Shelkovnikova, 2019). This general property 
provides a possible reason for broad scale impact on RNA metabolism by the ALS-causing 
mutations. However, not all ALS genes are RBPs by nature.   
Some ALS-linked mutations, such as those in SOD1, may induce pathological RNA binding 
properties and sequester RBPs or other gene products from their normal biological function 
(Lu et al., 2007). Similar toxic gain-of-function may result in C9ORF72 cases through 
hexanucleotide GGGGCC (G4C2) repeat expansion-created RNA species or through 
dipeptide repeat proteins (DPR) that bind and sequester essential RBPs (Barker, Niblock, 
Lee, Shaw, & Gallo, 2017). Although our understanding of RNA metabolism in ALS has 
improved in recent years, relatively little is known on how these processes could be 
mechanistically involved in skeletal muscle pathology observed in ALS, or indeed, in the 
etiopathogenesis of the disease itself.  
 
TDP-43 is a nucleic acid–binding protein whose mislocalization and aggregation in neurons 
represents a widely recognized hallmark in pathology of sporadic and most familial ALS 
cases. In normal cells TDP-43, a product of TARDBP gene, is mostly localized in the nucleus, 
notably in paraspeckles, where it primarily regulates transcription and pre-mRNA splicing. 
However, upon cellular stress and in ALS it localizes to cytoplasmic stress granules or similar 
inclusions, which may cause dysregulation of its normal nuclear targets (Zhao, Kim, van 
Bruggen, & Park, 2018). TDP-43 is essential for in vitro skeletal muscle cell differentiation 
and required for skeletal muscle regeneration in vivo (Vogler et al., 2018). Interestingly, 
phosphorylated TDP-43 has been shown to aggregate in the skeletal muscle of sporadic and 
familial ALS samples (Matthew D. Cykowski et al., 2018), although is not yet clear whether 
the aggregation and mislocalization plays an active role in the disease or reflects the altered 
homeostatic response to the neuronal pathology. Supporting the active role in normal 
muscle function, the Drosophila ortholog of TDP-43 promotes the formation and growth of 
neuromuscular synapses and its muscle-specific downregulation greatly decreases the 
locomotor capacity and lifespan (Strah et al., 2020). Analogous to the described role of TDP-
43 in local translation of mRNA in neurons (Alami et al., 2014), it was recently demonstrated 
that TDP-43 forms cytoplasmic, mRNA containing amyloid-like assemblies during normal 
regeneration of skeletal muscle (Vogler et al., 2018). These temporary structures that the 
authors coined myo-granules, contain mRNAs encoding sarcomeric proteins and are lost in 
fully mature myotubes. Although myo-granules seem to form an essential regenerative 
response in normal muscle regeneration, it remains possible that conditions associated with 
TDP-43 mislocalization, such as ALS, may alter the balance of assembly and clearance of 
these structures in the skeletal muscle.  
 
Similar to TDP-43, FUS protein plays an essential role in mRNA splicing and localization, 
stress granule formation, and other aspects of RNA metabolism. However, unlike loss of 
TDP-43, postnatal elimination of FUS has no effect on motor neuron function (Sharma et al., 
2016) suggesting that FUS-dependent motor degeneration is a gain of function conferred by 
ALS mutations. ALS-mutant FUS is intrinsically toxic to both muscle cells and motor neurons, 
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and in the muscle the toxicity is at least partially attributable to defective transcriptional 
regulation of acetylcholine receptor subunits in subsynaptic myonuclei (Picchiarelli et al., 
2019). As a result, knock-in mice expressing mutant FUS suffer from denervation of 
neuromuscular endplates before motor neuron loss, which is consistent with a 'dying-back' 
model.  Of note, FUS is a member the structurally similar to FET protein family consisting of 
three ALS genes (FUS, EWS and TAF15) all of which are present in skeletal muscle and 
mutations in which can cause muscle defects involving mitochondrial function (Picchiarelli & 
Dupuis, 2020). FUS is also an essential component of nuclear paraspeckles and can be found 
in recently discovered nuclear stress-induced silencing complex responsible for nuclear 
transport of small nucleotide sequences, including miRNAs (Castanotto et al., 2018). Finally, 
FUS is involved in optimal miRNA-mediated gene silencing as a component of cytosolic 
miRISC, where it interacts with the core miRNA-binding proteins of Argonaute (AGO) family. 
However, whether to what extent these specific foci are affected by FUS mutations in ALS 
muscles is currently unknown.  
 
Hexanucleotide repeat expansion in C9ORF72 gene results in production of G4C2 repeat 
RNA and DPR derived from these transcripts, and both of these products may sequester 
low-complexity domain-containing proteins that have critical function in RNA metabolism 
and in the formation of cytoplasmic and nuclear RNA foci. G4C2 repeat-associated RNA foci 
and DPR are present in the skeletal muscle of at least in fly (Freibaum et al., 2015) and 
zebrafish (Shaw et al., 2018) models of C9ALS. Although the main target of the fly studies 
was the central nervous system, it was shown that muscle-specific expression of G4C2 
causes age-dependent flight muscle defects as witnessed permanent abnormal wing 
position (Freibaum et al., 2015). Recent studies have revealed the presence of DPRs in 
C9ALS patient muscle (M. D. Cykowski et al., 2019) and increased amount of RNA foci in 
iPSC-derived skeletal myofibers from C9ALS patients (Swartz et al., 2016). In the latter case, 
the C9orf72 repeat expansion did not affect the efficiency of myoblast differentiation 
compared with controls cells, suggesting a limited role for skeletal muscle physiology in 
vitro. However, more studies are warranted to investigate if the expression of mutant 
C9ORF72 transcripts specifically in skeletal muscle in vivo could contribute to the ALS 
phenotype.  
 
Like the native product of C9ORF72, SOD1 does not contain RNA-binding motifs. However, 
as a result from a gain-of-function due to abnormal exposure of parts of the SOD1 
polypeptide that can bind nucleic acids, misfolded mutant SOD1 can bind specific mRNAs to 
regulate their expression or stability by selectively binding AU-rich elements (AREs) found in 
the 3' untranslated regions (Lu et al., 2007). The target mRNAs of misfolded SOD1 include 
vascular endothelial growth factor VEGF whose overexpression in skeletal muscle has been 
shown to be beneficial in mutant SOD1 mice (Azzouz et al., 2004). Remarkably, the 
interaction of mutant SOD1 with VEGF mRNA also results in abnormal recruitment of other 
ARE-binding proteins (Li et al., 2009) such as ELAVL1/HuR that normally facilitates muscle 
regeneration by promoting expression of myogenic factors MyoD and myogenin. Thus, 
mutant SOD1-initiated titration of protective factors such as ELAVL1/HuR may impair post-
transcriptional regulation by sequestering key regulatory RNA-binding proteins from their 
normal targets. In turn, this could contribute to the previously described truncated 
myogenic response in SOD1-G93A mice, where an induction is seen in RNA but not in 
protein level (Manzano, Toivonen, Olivan, et al., 2011).  
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MicroRNAs regulate gene expression post-transcriptionally through the binding to their 
specific target mRNAs and promoting mRNA degradation or translational repression. This 
regulation relies on a cytoplasmic miRNA-induced silencing complex (miRISC), a 
ribonucleoprotein complex that incorporates the miRNA and uses it as a template to 
recognize the target transcripts. Several miRNAs have been described altered in skeletal 
muscle in ALS and its models (Di Pietro, Lattanzi, & Bernardini, 2018). Most notably, 
denervation-inducible, skeletal muscle –enriched miR-206 has been shown to progressively 
increase with the advancing pathology in the fast twitch (but not slow twitch) muscles of 
SOD1-G93A mice (Toivonen et al., 2014). The presence of miR-206 has been shown to 
protect ALS mice by promoting NMJ stabilization, at least partially through inhibition of 
histone deacetylase HDAC4 and the following induction of FGF signalling to stimulate 
reinnervation (Williams et al., 2009). In agreement, muscle biopsies from patients with 
genetic forms of ALS show strong upregulation of miR-206 and a decreased expression of 
HDAC4 protein levels (Pegoraro, Marozzo, & Angelini, 2020). However, like in the case or 
MRF where the transcript levels do not translate in the increased protein levels (Manzano, 
Toivonen, Oliván, et al., 2011), the upregulation of miR-206 is not sufficient to inhibit 
ultimate denervation accompanied with ALS. One of the potential reasons could be that its 
incorporation into functional miRISC complexes might be affected by the disease. 
Interestingly, TDP-43 and FUS interact with the core miRNA-binding proteins of Argonaute 
(AGO) and are directly involved in the miRISC formation. Furthermore, TDP-43 has been 
shown to specifically disrupt miR1/miR-206 incorporation with miRISC in muscle cells, thus 
dampening its biological activity (King et al., 2014). Although the role of TDP-43 mutations 
associated with ALS have not been yet evaluated in the context of such miRNA damping, it 
remains plausible that documented cytoplasmic accumulation of TDP-43 in the context of 
most ALS mutations may have direct consequences on reinnervation capacity of ALS 
muscles through modulation of retrograde signalling (HDAC4-FGF axis) to the NMJ. 
 
Finally, since many characterized ALS-causing genes encode RBPs it is not surprising that 
also other RNA species that interact with these proteins might participate in ALS onset or 
disease progression. Long-noncoding RNAs (lncRNAs) regulate gene expression through 
diverse mechanisms, including modulation of transcription, direct antisense-mediated 
mRNA stabilization or destabilization, inhibition or stimulation of protein translation 
through modifications of ribosome activity, and indirect stabilization of mRNAs through 
miRNA sequestration (sponging). Additionally, many lncRNAs function as scaffolds to bring 
together multiple proteins to form ubiquitous RNP complexes such as paraspeckles and 
stress granules. One of the lncRNAs deregulated in ALS is NEAT1, a paraspeckle scaffold RNA 
that has been shown to bind ALS-linked proteins such as TDP-43, FUS and MATR3 (Banerjee, 
Vest, Pavlath, & Corbett, 2017; Nishimoto et al., 2013). NEAT1 levels are induced during 
myoblast differentiation, which suggests that NEAT1 and augmented paraspeckle activity 
may be critical for normal muscle cell function and regeneration. In skeletal muscle in vivo, 
MATR3 is essential for myogenesis and directly regulates the levels NEAT1. Regarding to 
other non-coding RNAs, circular RNAs (circRNAs) can also serve as RNA-miRNA sponges or as 
scaffolds for RNA-binding proteins. At this point, only one study has explored the possibility 
of differential circRNA regulation in ALS, and several candidates were found in blood of ALS 
patient-derived samples (Dolinar, Koritnik, Glavač, & Ravnik-Glavač, 2019). circRNAs are 
generated by back-splicing during pre-mRNA processing, and are resistant to RNA 
exonucleases. The circular form confers them highly stable in cells, which is a desired 
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feature for biomarker purposes. However, to date, there is no information on potential 
circRNA modifications in solid tissues such as nervous system or skeletal muscle. 
 
DEFECTS IN MUSCLE REGENERATION AND RESIDENT STEM CELLS  
In adults, myogenesis occurs after a stimulus that challenges skeletal muscle structure or 
function, that is denervation, intense exercise, injury of disease. It relies on the activation 
and differentiation of tissue-committed stem cells, so-called satellite cells. Satellite cells are 
mitotically quiescent and positive for Pax7, but after receiving the appropriate stimuli, enter 
cell cycle to become myoblasts and undergo multiple rounds of division. Part of this progeny 
will return to quiescence as a self-renewal mechanism to maintain the satellite cell pool, 
while others will proceed to terminal differentiation and fusion with each other to form 
multinucleated myofibers or with the parental myofiber to repair the injury. These events 
are controlled by a series of transcription factors called myogenic regulatory factors (MRFs). 
The first identified was myogenic determination factor 1 (MYOD1) and latter myogenic 
factor 5 (MYF5), myogenin, and herculin (MRF4). MRFs form homodimers and heterodimers 
and through their basic helix-loop-helix domain (bHLH) bind specific sequences in DNA 
called E-boxes (CANNTG) that are ubiquitously found in promoter and enhancer regions of 
different muscle and non-muscle specific genes. Even if other muscle-resident stem cells like 
mesenchymal or adipose-tissue-derived cells have been shown to possess the ability to 
enter the myogenic program upon the appropriate stimuli, their actual contribution to in 
vivo muscle repair and regeneration remains controversial (Madaro et al., 2018). 
In ALS, evidences from different groups have demonstrated an impairment in skeletal 
muscle satellite cell activity and myogenic potential. In this sense, when the P56S mutation 
in VAPB gene, associated to ALS type-8 (ALS8)(Nishimura et al., 2004), is introduced in the 
murine C2C12 myoblast cell line, the IRE1-XBP1 pathway (which is involved in the unfolded 
protein response) is impaired and aberrant myonuclear location is observed, which is 
associated with a reduced myotube formation in these cells (Yukako Tokutake et al., 2015). 
In this line, in the ALS mouse model SOD1-G93A our group has previously described a 
progressive upregulation in Pax7 and myogenic regulatory factors transcripts (MyoD1 and 
Myogenin) in skeletal muscle (Manzano, Toivonen, Olivan, et al., 2011). Moreover, in 
satellite cells harvested from these animals, we were first to report a reduced proliferative 
capacity from presymptomatic disease stages (Manzano et al., 2013). This was accompanied 
by a reduction in the number of Pax7-positive satellite cells and increased number of 
activated (MYOD1-positive) cells per myofiber (Manzano et al., 2012). Interestingly, a 
different pattern was observed in myofibers isolated from fast-twitch extensor digitorum 
longus (EDL) and slow-twitch soleus (SOL) muscles, which is in agreement with the longer 
resistance of this last myofiber type to denervation and weakness induced muscle atrophy 
in ALS.  
In ALS patient samples, using quantitative electron microscopy in skeletal muscle biopsies, 
Ishimoto et al. reported an increased euchromatin percentage in satellite cells (indicative of 
an active transcription and cell cycling) but without an increment in satellite cell numbers 
(Ishimoto, Goto, Ohta, & Kuroiwa, 1983). This is in agreement with a reduction in transcripts 
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for PAX7 and MYF5 myogenic markers observed by Jensen et al. and with the majority of 
those PAX7 positive satellite cells being negative for MYOD (Jensen, Jørgensen, Bech, 
Frandsen, & Schrøder, 2016). Other, immunohistochemical analyses have also revealed 
various degrees of denervation- and reinnervation with satellite cell activation (P.-F. Pradat 
et al., 2011). These data are thus indicative of in vivo activation of satellite cells in ALS 
patient skeletal muscle but without a progression through the myogenic program.  
This was confirmed in vitro when only a subset of these cells were able to generate colonies 
when harvested and put in culture, displaying an altered senescent-like morphology and 
increase of senescence associated βGal activity and CDKN2A/p16 expression, with a large 
number of vacuoles (P.-F. Pradat et al., 2011). Besides, for those cultures viable, ALS-derived 
satellite cells are unable to fully differentiate as shown by abnormal myotube morphology 
and reduced MYF-4 and myosin heavy chain isoform 1 gene and protein expression 
compared to controls (P.-F. Pradat et al., 2011; Scaramozza et al., 2014). 
Besides MRFs, myogenesis is regulated post-transcriptionally by muscle-specific microRNAs, 
so-called myomiRs. MicroRNAs are short (18-22 nt) oligonucleotides that bind the 
3’untranslated region of specific target mRNAs, inducing their degradation or blocking 
translation. A subset of them (miR-1, miR-133a, miR-133b, miR-206, miR-208a, miR-208b, 
and miR-499) are striated muscle-specific, with miR-206 and miR-133b expression restricted 
to skeletal muscle, and miR-208a to cardiac muscle.  This specificity is due to their genomic 
location within introns of myosin heavy chain genes or their transcriptional control by 
muscle specific transcriptional factors such as MyoD1. Importantly, myomiR functions 
partially overlap and regulate myoblast proliferation and differentiation, muscle 
regeneration, or fibre-type specification.  
In EDL fast-twitch muscles (preferably affected in the disease) from SOD1-G93A mice, our 
group has previously reported an increase in mature miR-206, with highest expression 
towards the most severely affected animals (Toivonen et al., 2014). Moreover, microRNA-
206 depletion was latter shown to accelerate disease progression and diminish survival by 
~1 month in the SOD1-G93A mouse, and this was accompanied by exacerbated muscle 
atrophy (Williams et al., 2009). These authors also demonstrated that miR-206 upregulation 
protects neuromuscular junctions after nerve injury promoting reinnervation, which may 
contribute to its beneficial effects in ALS. These results were confirmed skeletal muscle 
biopsies from patients with genetic forms of ALS (carrying mutations in C9orf72 and SOD1 
genes), where elevated levels of miRNA-206 were found, together with miR-23a, miR-29b, 
miR-31, and miR-455 (Russell et al., 2013).  
In line with the contribution of incomplete muscle regeneration and stem cell pathology to 
disease progression in ALS, several therapeutic strategies have targeted this mechanism.  
In the SOD1-G93A mouse, muscle-restricted expression of insulin-like growth factor-1 
isoform preserved myofiber structure and enhanced satellite cell regeneration, activating 
calcineurin-mediated pathways and anti-apoptotic Bcl-2 and reducing Caspase-1. This was 
accompanied by reduced motor neuron death, delayed disease onset and progression, 
extending the live span of the animals by 30 days (G. Dobrowolny et al., 2008; Gabriella 
Dobrowolny et al., 2005). However, it cannot be ruled out that diffusion of IGF1 secreted by 
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skeletal muscle into nearby NMJ and its known retrograde signalling into motor neurons 
(Caroni & Grandes, 1990) contribute to these findings. Indeed, reduction of mutant SOD1 
expression exclusively in skeletal muscle, by gene excision, lentivirus- or AAV-encoded siRNA 
to SOD1 did not alter disease onset, progression or survival in these mouse models (Miller et 
al., 2006).  
 
In a different study, activation of P2X7 ionotrophic receptor in the SOD1-G93A mouse 
skeletal muscle stimulated the myogenic program from satellite cells and preserved the 
morphology of neuromuscular junctions, reducing denervation and atrophy of skeletal 
muscles in these mice (Fabbrizio et al., 2019). Granulocyte colony-stimulating factor 
(GCSF/CSF3) is a cytokine used to prevent neutropenia in patients receiving 
myelosuppressive anticancer drugs and has been also shown to increase neurogenesis and 
neuroplasticity and boost muscle regeneration in Duchenne muscular dystrophy mice. In our 
experience, SOD1-G93A mice treated with GCSF subcutaneously showed delayed disease 
onset, improved motor performance and prolonged survival compared to non-treated 
controls and this was followed by reduced neuromuscular junction dismantling and an 
increase in satellite cell proliferation (Rando et al., 2017). Following a different approach, 
cell therapy implants of mesenchymal stem cells (MSCs) in skeletal muscle of ALS mice and 
rats increased longevity with improved motor function and decreased motorneuron 
degeneration in the spinal cord. These effects have been explained by secretion of glial-
derived neurotrophic factor and neurotrophin 4 by MSCs in the grafted muscles and the 
neuromuscular junction (Rando et al., 2018; Suzuki et al., 2008). Taking together these 
results suggest that stimulation of satellite cell activity and muscle regeneration may be 
therapeutic in ALS patients. Mesenchymal stem cells have been also transplanted into 
skeletal muscles of ALS patients demonstrating engraftment and low toxicity (Table 1). 
Beyond neurotrophic supply, transplanted cells have been suggested to regulate 
inflammation in skeletal muscle.  
In this sense, a finely tuned cross-talk between immune system and muscle-resident stem 
cells is necessary for muscle regeneration. Besides satellite cell activation and proliferation, 
muscle injury promotes recruitment of neutrophils, monocytes and CD8+ T cells to the site 
of trauma through the release of cytokines and CC-chemokine ligand 2 (CCL2) and CXC-
chemokine ligand 1 (CXCL1) originating a primary inflammatory response orchestrated by 
interferon-γ (IFNγ) and tumour necrosis factor (TNF). Cytokines also induce the expression 
of MRFs genes by the myogenic progenitors, that together with IGF1 released by M1-
macrophages contribute towards the satellite cell proliferation to expand the myogenic pool 
(for review see (Tidball, 2017)). A further production of amphiregulin by regulatory T cells 
increases the expression of myogenic-regulatory factors that drive the later stages of the 
myofiber differentiation and maturation (Schiaffino, Pereira, Ciciliot, & Rovere-Querini, 
2017). Other cells present in skeletal muscle interstitium such as fibroadipogenic 
progenitors (FAPs) and regulated by transforming growth factor-β (TGFβ) (from 
macrophages) and by IL-4 (from eosinophils), differentiate into fibroblast to produce 
extracellular matrix components that will be the scaffold for the new myofiber and release 
IGF1 to promote its growth (Heredia et al., 2013; Ismaeel et al., 2019).  
 
In ALS, macrophage infiltration and increased inflammatory cytokines (IL-1β and TNF-) 
have been reported in skeletal muscle from patients and rat models, (Van Dyke et al., 2016). 
Moreover, terminal complement activation has been observed in tibialis anterior from 
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SOD1-G93A mice, with increased levels of C1qB, C4, fB, C3 and C5a, contributing to recruitment 
of C5aR1-positive macrophages into this tissue (H. A. Wang, Lee, Lee, Woodruff, & Noakes, 
2017). Interestingly, genetic ablation of C5ar1 gene or systemic inhibition of C5a–C5aR1 
signalling ameliorated disease pathology, reduced hind limb weakness and paralysis and 
extended the survival of these mice (Trent M. Woodruff et al., 2008; T. M. Woodruff, Lee, & 
Noakes, 2014). 
Accumulation of degranulating mast cells associated with neutrophils have been also 
observed in myofibers and motor endplates from ALS patients and SOD1-G93A rats, and 
have been suggested to contribute to denervation (E. Trias et al., 2017; Emiliano Trias et al., 
2018). Consistently, treatment of symptomatic SOD1-G93A rats with Masitinib, a tyrosine 
kinase inhibitor, prevented mast cell and neutrophil infiltration in skeletal muscle, axonal 
pathology, secondary demyelination, and the loss of type 2B myofibers (Emiliano Trias et al., 
2018). Of note, a double-blinded and placebo-controlled Phase 2/3 clinical trial recently 
confirmed a reduced functional decline as measured by ALSFRS-R scale, in non-fast 
progressing ALS patients (Table 1) (Mora et al., 2020).  
On the other hand, upregulation of TGFβ levels and increase in the numbers of FAPs in 
skeletal muscle have been observed in SOD1-G93A mice correlating with myogenesis 
deficiencies and fibrosis in this tissue (Gonzalez et al., 2017). 
Taking together, these results suggest that inflammation in skeletal muscle of ALS patients 
and animal models contribute to denervation and dysfunctional muscle regeneration 
observed in the disease and modulation of inflammatory cytokines and cells represent a 
promising therapeutic strategy. Since all the previous studies have been carried out using 
systemic delivery of drugs or ubiquitously expressed gene modifications, it remains to be 
analysed if and how restricted immune system modulation in skeletal muscle will influence 
disease pathogenesis. 
 
Physiologically, micro-injuries generated after acute and endurance training have been also 
shown to activate satellite cells and myogenesis in skeletal muscle, being this response age, 
gender, fiber-type and exercise dependent. However, the effect of exercise for ALS course 
has been long discussed (see (Braga, Pinto, Pinto, & de Carvalho, 2018; Kato, Hashida, & 
Konaka, 2018; Tsitkanou, Della Gatta, Foletta, & Russell, 2019) for review). Some studies 
have linked physical activity to increased production of reactive oxygen species and 
oxidative stress, thus worsening the physical condition and motor neuron degeneration in 
ALS. Others have reported beneficial outcomes with mild to moderate training in ALS 
patients and animal models (Table 1). In this sense, swimming-based training preserved the 
number, cross-section area and fiber-type distribution of myofibers in the ALS mice and 
limited hypotrophy in both slow- and fast- twitch muscles (Deforges et al., 2009). 
 
CONCLUDING REMARKS 
Evidences of participation of skeletal muscle in ALS etiopathogeny arise from several 
perspectives. Pathogenic findings in the disease suggest an early dismantling of NMJ (dying-
back) with destruction of postsynaptic apparatus and late axonal and motor neuron cell 
body degeneration (Fischer et al., 2004; Pun et al., 2006). Moreover, ALS deregulates 
molecular mechanisms that are critical for skeletal muscle homeostasis including energy 
handling through mitochondrial respiratory chain (skeletal muscle is a major ATP consumer); 
proteostasis, which conditions the ratio between protein synthesis and degradation and, 
thus, maintenance of skeletal muscle mass; and the activity of stem cells responsible for 
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regenerating a tissue that is constantly stressed by cytoskeletal actin-myosin contraction. 
Therapeutic approaches targeting the above mentioned pathways in skeletal muscle, have 
frequently ameliorated disease progression and extended survival in mouse models. 
Conversely, mutation of genes associated with ALS such as SOD1, restricted into skeletal 
muscle mimicked disease hallmarks including NMJ disruption, muscle atrophy and MTN 
degeneration. 
The intimate connection between myofibers and nervous system through motor endplate, 
halts discerning between pathogenic events in each tissue. Moreover, reciprocal interaction 
between molecular mechanisms in skeletal muscle and systemic conditions such as 
hormonal, inflammatory and nutritional status or physical activity of the individual impedes 
to delineate a cause-effect pattern. Nevertheless, gaining insight into molecular 
mechanisms underlying ALS pathology in skeletal muscle including NMJ rearrangement, 
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Figure 1. Regulatory network in skeletal muscle that contributes to ALS disease pathology.  
The image recapitulates the molecular mechanisms involved in skeletal muscle toxicity in 
ALS as discussed in the text, mitochondrial dysfunction and muscle metabolism, 
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Figure 2. Mechanisms proposed for proteostasis impairment in ALS skeletal muscle. A 
general translational repression has been demonstrated in ALS, based on sequestering of 
mRNA and transcriptional machinery components by stress granules and mutant protein 
aggregates. The reduction in chaperon protein synthesis also halts refolding of mutant 
misfolded proteins during the unfolded protein response (UPR). Autophagy and 
proteasomal catalytic pathways show incomplete activation or function based on reduced 
synthesis of promoters (i.e. Beclin 1) or abnormal autophagolysosomal fusion and cargo 
degradation. Impairment of UPR and catalytic pathways for misfolded mutant proteins lead 
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Table 1. Clinical trials using drugs that target molecular mechanisms altered in ALS skeletal 
muscle. According to the National Institutes of Health (NIH) clinical trial database((NIH)), 
681 clinical trials have been or are currently under conduction in ALS patients, 366 of them 
with expected outcomes in skeletal muscle structure or function. This table represents an 
overview of the clinical trials in ALS using drugs that are known regulators of proteostasis, 
muscle regeneration and stem cell therapy, mitochondrial function and RNA metabolism. 
 
 Drug/approach Phase Mechanism of 
action 
Identifier 
Proteostasis Colchicine II Enhancement of 
translation of Heat 
shock and other 
autophagy proteins 
NCT03693781 
 Rapamycine II Autophagy activator NCT03359538 
 Guanabenz II inhibition of eIF2α 
dephosphorylation 
and stimulation of UPR 
(Bella et al., 
2017) 






and Stem cell 
transplantation 























 Masitinib 2/3 Inflammatory 
modulation 
NCT03127267 
 Insulin like growth 
factor, type 1 




(Borasio et al., 











 Bone marrow derived-
Mesenchymal Stem 
Cells 


















 Umbilical Cord 
Mesenchymal Stem 
Cells 




 Adipose tissue 
derived-Mesenchymal 
stem cells 





















 OECs: olfactory 
ensheathing cells 
Pilot Stem cell 
transplantation 
(L. Chen et al., 
2012; Lin 
Chen et al., 
2007; Huang 
et al., 2008) 











CoQ10, vitamin E, N-Ac 
cysteine, and L-cystine 
II Antioxidant NCT04244630 


















 Tamoxifen II Upregulation of 
mitochondria 
respiratory chain  
NCT00214110 
 Creatine II ATP source NCT00005674 
 Creatine Monohydrate III ATP source NCT00069186 
RNA Antisense 
oligonucleotides 
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